| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CIS3 |
| Uniprot No | P47001 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 65-227aa |
| 氨基酸序列 | DVISQIGDGQVQATSAATAQATDSQAQATTTATPTSSEKISSSASKTSTNATSSSCATPSLKDSSCKNSGTLELTLKDGVLTDAKGRIGSIVANRQFQFDGPPPQAGAIYAAGWSITEDGYLALGDSDVFYQCLSGNFYNLYDQNVAEQCSAIHLEAVSLVDC |
| 预测分子量 | 24.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CIS3(SOCS3)重组蛋白的3篇参考文献示例，涵盖其功能、制备及应用研究：
---
1. **文献名称**：*SOCS3 is a physiological negative regulator of G-CSF signaling and emergency granulopoiesis*
**作者**：Yasukawa, H. et al.
**摘要**：该研究利用重组SOCS3蛋白，揭示其在抑制粒细胞集落刺激因子(G-CSF)信号通路中的作用，证实SOCS3通过结合JAK激酶负调控造血干细胞分化，为炎症相关疾病的治疗提供依据。
2. **文献名称**：*Expression and purification of functional recombinant SOCS3 in Escherichia coli*
**作者**：Sasaki, A. et al.
**摘要**：文章描述了一种在大肠杆菌中高效表达重组SOCS3蛋白的方法，并通过体外实验验证其抑制IL-6信号通路的功能，为大规模制备活性SOCS3蛋白提供技术参考。
3. **文献名称**：*SOCS3 recombinant protein attenuates adipose tissue inflammation and insulin resistance in diabetic mice*
**作者**：Jo, D. et al.
**摘要**：研究通过注射重组SOCS3蛋白，证明其可减轻2型糖尿病小鼠脂肪组织炎症、改善胰岛素敏感性，提示SOCS3在代谢性疾病中的潜在治疗价值。
---
**注**：CIS3常被称为SOCS3(Suppressor of Cytokine Signaling 3)，上述文献基于其重组蛋白的研究方向整理，实际文献可能存在名称差异，建议通过PubMed等数据库以“SOCS3 recombinant protein”为关键词进一步检索。
CIS3 (Cytokine-Inducible SH2-Containing Protein 3), also known as SOCS3 (Suppressor of Cytokine Signaling 3), is a critical regulatory protein involved in modulating cellular responses to cytokines and growth factors. Discovered in the late 1990s as part of the SOCS family, CIS3 functions as a negative feedback inhibitor of cytokine signaling pathways, particularly the JAK-STAT (Janus Kinase-Signal Transducer and Activator of Transcription) cascade. Its expression is rapidly induced by cytokines such as interleukin-6 (IL-6), leptin, and interferons, enabling precise control over immune responses, inflammation, and cellular homeostasis.
Structurally, CIS3 contains a central SH2 domain that binds phosphorylated tyrosine residues on cytokine receptors or JAK kinases, and a C-terminal SOCS box that recruits ubiquitin ligase complexes to degrade target proteins. This dual mechanism allows CIS3 to suppress prolonged activation of signaling pathways, preventing excessive immune reactions or uncontrolled cell proliferation. Dysregulation of CIS3 is linked to pathologies including autoimmune diseases, metabolic disorders, and cancer, highlighting its therapeutic potential.
Recombinant CIS3 protein is produced using expression systems like *E. coli* or mammalian cells, ensuring high purity and bioactivity for research. It serves as a tool to study signaling inhibition mechanisms, screen drug candidates, or develop protein-based therapies. Recent studies also explore engineered CIS3 variants to enhance stability or specificity for clinical applications. Its role in metabolic regulation and immune modulation continues to drive interest in targeting CIS3 for treating conditions like obesity, diabetes, and inflammatory disorders.
×
